Objectives Concerns have arisen recently over the relationship between body mass index
(BMI) and outcomes in atrial fibrillation (AF) patients with direct oral anticoagulants (DOACs) …

Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …

Background: It is unclear whether the overall effectiveness and safety of direct oral
anticoagulants (DOACs) are consistent in patients with nonvalvular atrial fibrillation (AF) and …

Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …

Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …

Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …

Background and Purpose—Obesity is a risk factor for all-cause and cardiovascular death
but, despite this, an inverse relationship between overweight or obesity and a better …

Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …

Aims To investigate the relationship between body mass index (BMI) and outcomes in
patients with atrial fibrillation (AF). Methods and results In the ENGAGE AF-TIMI 48 trial …

Background There is a paucity of evidence regarding the effects of non-vitamin K antagonist
oral anticoagulants (NOACs) in underweight patients with atrial fibrillation (AF). Objective …